New p-tau217 blood tests for Alzheimer's detection may boost Eli Lilly and Biogen healthcare stocks.
New blood tests for p-tau217 protein could improve early detection of Alzheimer's, potentially boosting healthcare stocks Eli Lilly and Biogen, which already have FDA-approved Alzheimer's treatments. Eli Lilly's Kisunla has demonstrated potential to slow disease progression by 35%, and Biogen's Leqembi could see a monthly injectable version approved by January. These blood tests, if approved, could positively impact both companies' stocks for healthcare investors.
August 11, 2024
3 Articles